Dendritic cell subsets in type 1 diabetes: Friend or foe?

Frontiers in Immunology

Volumn 4, Issue DEC, 2013, Pages

  Morel, Penelope A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmunity; Dendritic cells; T regulatory cells; Tolerance; Type 1 diabetes

Indexed keywords

EID: 84892143449     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00415     Document Type: Review

References (169)

1. Atkinson MA, Bluestone JA, Eisenbarth GS, Hebrok M, Herold KC, Accili D, et al. How does type 1 diabetes develop? The notion of homicide or beta-cell suicide revisited. Diabetes (2011) 60(5):1370-9. doi:10.2337/db10-1797.
2. Calderon B, Unanue ER. Antigen presentation events in autoimmune diabetes. Curr Opin Immunol (2012) 24(1):119-28. doi:10.1016/j.coi.2011.11.005.
3. Leiter EH, Prochazka M, Coleman DL. Animal model of human disease, the nonobese diabetic (NOD) mouse. Am J Pathol (1987) 128:380-3.
4. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med (1973) 137(5):1142-62. doi:10.1084/jem.137.5.1142.
5. Steinman RM, Lustig DS, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. 3. Functional properties in vivo. J Exp Med (1974) 139(6):1431-45. doi:10.1084/jem.139.6.1431.
6. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. II. Functional properties in vitro. J Exp Med (1974) 139(2):380-97. doi:10.1084/jem.139.6.1431.
7. Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol (2013) 31(1):563-604. doi:10.1146/annurev-immunol-020711-074950.
8. Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A (2002) 99(1):351-8. doi:10.1073/pnas.231606698.
9. Reizis B, Bunin A, Ghosh HS, Lewis KL, Sisirak V. Plasmacytoid dendritic cells: recent progress and open questions. Annu Rev Immunol (2011) 29(1):163-83. doi:10.1146/annurev-immunol-031210-101345.
10. Onai N, Kurabayashi K, Hosoi-Amaike M, Toyama-Sorimachi N, Matsushima K, Inaba K, et al. A clonogenic progenitor with prominent plasmacytoid dendritic cell developmental potential. Immunity (2013) 38(5):943-57. doi:10.1016/j.immuni.2013.04.006.
11. Schraml Barbara U, van Blijswijk J, Zelenay S, Whitney Paul G, Filby A, Acton Sophie E, et al. Genetic tracing via DNGR-1 expression history defines dendritic cells as a hematopoietic lineage. Cell (2013) 154(4):843-58. doi:10.1016/j.cell.2013.07.014.
12. Lewis Kanako L, Caton Michele L, Bogunovic M, Greter M, Grajkowska Lucja T, Ng D, et al. Notch2 receptor signaling controls functional differentiation of dendritic cells in the spleen and intestine. Immunity (2011) 35(5):780-91. doi:10.1016/j.immuni.2011.08.013.
13. Ganguly D, Haak S, Sisirak V, Reizis B. The role of dendritic cells in autoimmunity. Nat Rev Immunol (2013) 13(8):566-77. doi:10.1038/nri3477.
14. Nair-Gupta P, Blander JM. An updated view of the intracellualr mechanisms regulating cross-presentation. Front Immunol (2013) 4:401. doi:10.3389/fimmu.2013.00401.
15. Hochrein H, Shortman K, Vremec D, Scott B, Hertzog P, O'Keeffe M. Differential production of IL-12, IFN-alpha, and IFN-gamma by mouse dendritic cell subsets. J Immunol (2001) 166(9):5448-55.
16. Farrand KJ, Dickgreber N, Stoitzner P, Ronchese F, Petersen TR, Hermans IF. Langerin+ CD8alpha+ dendritic cells are critical for cross-priming and IL-12 production in response to systemic antigens. J Immunol (2009) 183(12):7732-42. doi:10.4049/jimmunol.0902707.
17. Mattei F, Schiavoni G, Belardelli F, Tough DF. IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation. J Immunol (2001) 167(3):1179-87.
18. Pulendran B, Lingappa J, Kennedy MK, Smith J, Teepe M, Rudensky A, et al. Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice. J Immunol (1997) 159(5):2222-31.
19. Ohnmacht C, Pullner A, King SB, Drexler I, Meier S, Brocker T, et al. Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. J Exp Med (2009) 206(3):549-59. doi:10.1084/jem.20082394.
20. Liu K, Iyoda T, Saternus M, Kimura Y, Inaba K, Steinman RM. Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med (2002) 196(8):1091-7. doi:10.1084/jem.20021215.
21. Yamazaki S, Dudziak D, Heidkamp GF, Fiorese C, Bonito AJ, Inaba K, et al. CD8+CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory t cells. J Immunol (2008) 181(10):6923-33.
22. Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C, Yamazaki S, et al. Differential antigen processing by dendritic cell subsets in vivo. Science (2007) 315(5808):107-11. doi:10.1126/science.1136080.
23. Sun CM, Hall JA, Blank RB, Bouladoux N, Oukka M, Mora JR, et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med (2007) 204(8):1775-85. doi:10.1084/jem.20070602.
24. Coombes JL, Siddiqui KR, Arancibia-Carcamo CV, Hall J, Sun CM, Belkaid Y, et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med (2007) 204(8):1757-64. doi:10.1084/jem.20070590.
25. Proietto AI, van Dommelen S, Zhou P, Rizzitelli A, D'Amico A, Steptoe RJ, et al. Dendritic cells in the thymus contribute to T-regulatory cell induction. Proc Natl Acad Sci U S A (2008) 105(50):19869-74. doi:10.1073/pnas.0810268105.
26. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 299(5609):1057-61. doi:10.1126/science.1079490.
27. Abbas AK, Benoist C, Bluestone JA, Campbell DJ, Ghosh S, Hori S, et al. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol (2013) 14(4):307-8. doi:10.1038/ni.2554.
28. Wing K, Fehérvári Z, Sakaguchi S. Emerging possibilities in the development and function of regulatory T cells. Int Immunol (2006) 18(7):991-1000. doi:10.1093/intimm/dxl044.
29. Bergmann C, Strauss L, Zeidler R, Lang S, Whiteside TL. Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment. Cancer Immunol Immunother (2007) 56(9):1429-42. doi:10.1007/s00262-007-0280-9.
30. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol (2004) 172(9):5149-53.
31. Chambers ES, Hawrylowicz CM. The impact of vitamin D on regulatory T cells. Curr Allergy Asthma Rep (2011) 11(1):29-36. doi:10.1007/s11882-010-0161-8.
32. Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science (2007) 317(5835):256-60. doi:10.1126/science.1145697.
33. Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, von Boehmer H. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol (2005) 6(12):1219-27. doi:10.1038/ni1265.
34. Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med (2004) 199(11):1467-77. doi:10.1084/jem.20040180.
35. Yamazaki S, Bonito AJ, Spisek R, Dhodapkar M, Inaba K, Steinman RM. Dendritic cells are specialized accessory cells along with TGF- for the differentiation of Foxp3+ CD4+ regulatory T cells from peripheral Foxp3 precursors. Blood (2007) 110(13):4293-302. doi:10.1182/blood-2007-05-088831.
36. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med (2000) 192(9):1213-22. doi:10.1084/jem.192.9.1213.
37. Jonuleit H, Schmitt E, Steinbrink K, Enk AH. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol (2001) 22(7):394-400. doi:10.1016/S1471-4906(01)01952-4.
38. Roncarolo MG, Levings MK, Traversari C. Differentiation of T regulatory cells by immature dendritic cells. J Exp Med (2001) 193(2):F5-9. doi:10.1084/jem.193.2.F5.
39. Wakkach A, Fournier N, Brun V, Breittmayer JP, Cottrez F, Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity (2003) 18(5):605-17. doi:10.1016/S1074-7613(03)00113-4.
40. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor {zeta}-chain and induce a regulatory phenotype in naive T cells. J Immunol (2006) 176(11):6752-61.
41. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med (2002) 196(12):1627-38. doi:10.1084/jem.20021598.
42. Kretschmer K, Heng TS, von Boehmer H. De novo production of antigen-specific suppressor cells in vivo. Nat Protoc (2006) 1(2):653-61. doi:10.1038/nprot.2006.105.
43. Zou T, Caton AJ, Koretzky GA, Kambayashi T. Dendritic cells induce regulatory T cell proliferation through antigen-dependent and-independent interactions. J Immunol (2010) 185(5):2790-9. doi:10.4049/jimmunol.0903740.
44. Darrasse-Jeze G, Deroubaix S, Mouquet H, Victora GD, Eisenreich T, Yao KH, et al. Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J Exp Med (2009) 206(9):1853-62. doi:10.1084/jem.20090746.
45. Morel PA, Turner MS. Dendritic cells and the maintenance of self-tolerance. Immunol Res (2011) 50(2-3):124-9. doi:10.1007/s12026-011-8217-y.
46. Serreze DV, Gaskins HR, Leiter EH. Defects in the differentiation and function of antigen presenting cells in NOD/Lt mice. J Immunol (1993) 150(6):2534-43.
47. Prasad SJ, Goodnow CC. Cell-intrinsic effects of non-MHC NOD genes on dendritic cell generation in vivo. Int Immunol (2002) 14(6):677-84. doi:10.1093/intimm/dxf034.
48. Steptoe RJ, Ritchie JM, Harrison LC. Increased generation of dendritic cells from myeloid progenitors in autoimmune-prone nonobese diabetic mice. J Immunol (2002) 168:5032-41.
49. Feili-Hariri M, Morel PA. Phenotypic and functional characteristics of BM-derived DC from NOD and non diabetes-prone strains. Clin Immunol (2001) 98:133-42. doi:10.1006/clim.2000.4959.
50. Vasquez AC, Feili-Hariri M, Tan RJ, Morel PA. Qualitative and quantitative abnormalities in splenic dendritic cell populations in NOD mice. Clin Exp Immunol (2004) 135(2):209-18. doi:10.1111/j.1365-2249.2003.02359.x.
51. Marleau AM, Summers KL, Singh B. Differential contributions of APC subsets to T cell activation in nonobese diabetic mice. J Immunol (2008) 180(8):5235-49.
52. den Haan JM, Lehar SM, Bevan MJ. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med (2000) 192(12):1685-96. doi:10.1084/jem.192.12.1685.
53. Pettersson A, Wu XC, Ciumas C, Lian H, Chirsky V, Huang YM, et al. CD8alpha dendritic cells and immune protection from experimental allergic encephalomyelitis. Clin Exp Immunol (2004) 137(3):486-95. doi:10.1111/j.1365-2249.2004.02556.x.
54. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med (2001) 194(6):769-80. doi:10.1084/jem.194.6.769.
55. Chilton PM, Rezzoug F, Fugier-Vivier I, Weeter LA, Xu H, Huang Y, et al. Flt3-ligand treatment prevents diabetes in NOD mice. Diabetes (2004) 53(8):1995-2002. doi:10.2337/diabetes.53.8.1995.
56. O'Keeffe M, Brodnicki TC, Fancke B, Vremec D, Morahan G, Maraskovsky E, et al. Fms-like tyrosine kinase 3 ligand administration overcomes a genetically determined dendritic cell deficiency in NOD mice and protects against diabetes development. Int Immunol (2005) 17(3):307-14. doi:10.1093/intimm/dxh210.
57. Van Belle TL, Juntti T, Liao J, von Herrath MG. Pre-existing autoimmunity determines type 1 diabetes outcome after Flt3-ligand treatment. J Autoimmun (2010) 34(4):445-52. doi:10.1016/j.jaut.2009.11.010.
58. Poligone B, Weaver DJJ, Sen P, Baldwin ASJ, Tisch R. Elevated NF-kappaB activation in nonobese diabetic mouse dendritic cells results in enhanced APC function. J Immunol (2002) 168:188-96.
59. Weaver DJJ, Poligone B, Bui T, Abdel-Motal UM, Baldwin ASJ, Tisch R. Dendritic cells from nonobese diabetic mice exhibit a defect in NF-kappa B regulation due to a hyperactive I kappa B kinase. J Immunol (2001) 167:1461-8.
60. Marleau AM, Singh B. Myeloid dendritic cells in non-obese diabetic mice have elevated costimulatory and T helper-1-inducing abilities. J Autoimmun (2002) 19(1-2):23-35. doi:10.1006/jaut.2002.0597.
61. Liu J, Beller D. Aberrant production of IL-12 by macrophages from several autoimmune-prone mouse strains is characterized by intrinsic and unique patterns of NF-kappa B expression and binding to the IL-12 p40 promoter. J Immunol (2002) 169(1):581-6.
62. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med (2007) 204(6):1257-65. doi:10.1084/jem.20062512.
63. Mandapathil M, Hilldorfer B, Szczepanski MJ, Czystowska M, Szajnik M, Ren J, et al. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem (2010) 285(10):7176-86. doi:10.1074/jbc.M109.047423.
64. Ghaemi Oskouie F, Shameli A, Yang A, Desrosiers MD, Mucsi AD, Blackburn MR, et al. High levels of adenosine deaminase on dendritic cells promote autoreactive T cell activation and diabetes in nonobese diabetic mice. J Immunol (2011) 186(12):6798-806. doi:10.4049/jimmunol.1004222.
65. Liston A, Lesage S, Gray DH, O'Reilly LA, Strasser A, Fahrer AM, et al. Generalized resistance to thymic deletion in the NOD mouse; a polygenic trait characterized by defective induction of Bim. Immunity (2004) 21(6):817-30. doi:10.1016/j.immuni.2004.10.014.
66. Kreuwel HT, Biggs JA, Pilip IM, Pamer EG, Lo D, Sherman LA. Defective CD8+ T cell peripheral tolerance in nonobese diabetic mice. J Immunol (2001) 167(2):1112-7.
67. Tritt M, Sgouroudis E, d'Hennezel E, Albanese A, Piccirillo CA. Functional waning of naturally occurring CD4+ regulatory T-cells contributes to the onset of autoimmune diabetes. Diabetes (2008) 57(1):113-23. doi:10.2337/db06-1700.
68. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity (2000) 12(4):431-40. doi:10.1016/S1074-7613(00)80195-8.
69. Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol (2009) 10(11):1185-92. doi:10.1038/ni.1790.
70. Obst R, van Santen HM, Melamed R, Kamphorst AO, Benoist C, Mathis D. Sustained antigen presentation can promote an immunogenic T cell response, like dendritic cell activation. Proc Natl Acad Sci U S A (2007) 104(39):15460-5. doi:10.1073/pnas.0707331104.
71. Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity (2010) 33(2):153-65. doi:10.1016/j.immuni.2010.08.004.
72. Long SA, Cerosaletti K, Bollyky PL, Tatum M, Shilling H, Zhang S, et al. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes (2010) 59(2):407-15. doi:10.2337/db09-0694.
73. Anderson AC, Chandwaskar R, Lee DH, Kuchroo VK. Cutting edge: the Idd3 genetic interval determines regulatory T cell function through CD11b+CD11c-APC. J Immunol (2008) 181(11):7449-52.
74. Hamilton-Williams EE, Martinez X, Clark J, Howlett S, Hunter KM, Rainbow DB, et al. Expression of diabetes-associated genes by dendritic cells and CD4 T cells drives the loss of tolerance in nonobese diabetic mice. J Immunol (2009) 183(3):1533-41. doi:10.4049/jimmunol.0900428.
75. Sgouroudis E, Kornete M, Piccirillo CA. IL-2 production by dendritic cells promotes Foxp3(+) regulatory T-cell expansion in autoimmune-resistant NOD congenic mice. Autoimmunity (2011) 44(5):406-14. doi:10.3109/08916934.2010.536795.
76. Yang XD, Tisch R, Singer SM, Cao ZA, Liblau RS, Schreiber RD, et al. Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med (1994) 180(3):995-1004. doi:10.1084/jem.180.3.995.
77. Lee LF, Xu B, Michie SA, Beilhack GF, Warganich T, Turley S, et al. The role of TNF-alpha in the pathogenesis of type 1 diabetes in the nonobese diabetic mouse: analysis of dendritic cell maturation. Proc Natl Acad Sci U S A (2005) 102(44):15995-6000. doi:10.1073/pnas.0508122102.
78. Lee MH, Lee WH, Todorov I, Liu CP. CD4+ CD25+ regulatory T cells prevent type 1 diabetes preceded by dendritic cell-dominant invasive insulitis by affecting chemotaxis and local invasiveness of dendritic cells. J Immunol (2010) 185(4):2493-501. doi:10.4049/jimmunol.1001036.
79. Feili-Hariri M, Falkner DH, Morel PA. Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy. J Leukoc Biol (2005) 78:656-64. doi:10.1189/jlb.1104631.
80. Feili-Hariri M, Flores RR, Vasquez AC, Morel PA. Dendritic cell immunotherapy for autoimmune diabetes. Immunol Res (2006) 36(1-3):167-73. doi:10.1385/IR:36:1:167.
81. Saxena V, Ondr JK, Magnusen AF, Munn DH, Katz JD. The countervailing actions of myeloid and plasmacytoid dendritic cells control autoimmune diabetes in the nonobese diabetic mouse. J Immunol (2007) 179(8):5041-53.
82. Caielli S, Conforti-Andreoni C, Di Pietro C, Usuelli V, Badami E, Malosio ML, et al. On/off TLR signaling decides proinflammatory or tolerogenic dendritic cell maturation upon CD1d-mediated interaction with invariant NKT cells. J Immunol (2010) 185(12):7317-29. doi:10.4049/jimmunol.1000400.
83. Diana J, Brezar V, Beaudoin L, Dalod M, Mellor A, Tafuri A, et al. Viral infection prevents diabetes by inducing regulatory T cells through NKT cell-plasmacytoid dendritic cell interplay. J Exp Med (2011) 208(4):729-45. doi:10.1084/jem.20101692.
84. Li Q, Xu B, Michie SA, Rubins KH, Schreriber RD, McDevitt HO. Interferon-alpha initiates type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A (2008) 105(34):12439-44. doi:10.1073/pnas.0806439105.
85. Li Q, McDevitt HO. The role of interferon alpha in initiation of type I diabetes in the NOD mouse. Clin Immunol (2011) 140(1):3-7. doi:10.1016/j.clim.2011.04.010.
86. Diana J, Simoni Y, Furio L, Beaudoin L, Agerberth B, Barrat F, et al. Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat Med (2013) 19(1):65-73. doi:10.1038/nm.3042.
87. Creusot RJ. Initiating type I diabetes: new suspects in the lineup. Nat Med (2013) 19(1):18-20. doi:10.1038/nm.3044.
88. Swiecki M, McCartney SA, Wang Y, Colonna M. TLR7/9 versus TLR3/MDA5 signaling during virus infections and diabetes. J Leukoc Biol (2011) 90(4):691-701. doi:10.1189/jlb.0311166.
89. Alba A, Planas R, Clemente X, Carrillo J, Ampudia R, Puertas MC, et al. Natural killer cells are required for accelerated type 1 diabetes driven by interferon-beta. Clin Exp Immunol (2008) 151(3):467-75. doi:10.1111/j.1365-2249.2007.03580.x.
90. Dotta F, Censini S, van Halteren AG, Marselli L, Masini M, Dionisi S, et al. Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A (2007) 104(12):5115-20. doi:10.1073/pnas.0700442104.
91. von Herrath M. Diabetes: a virus-gene collaboration. Nature (2009) 459(7246):518-9. doi:10.1038/459518a.
92. Filippi CM, Estes EA, Oldham JE, von Herrath MG. Immunoregulatory mechanisms triggered by viral infections protect from type 1 diabetes in mice. J Clin Invest (2009) 119(6):1515-23. doi:10.1172/JCI38503.
93. Welzen-Coppens JM, van Helden-Meeuwsen CG, Leenen PJ, Drexhage HA, Versnel MA. The kinetics of plasmacytoid dendritic cell accumulation in the pancreas of the NOD mouse during the early phases of insulitis. PLoS One (2013) 8(1):e55071. doi:10.1371/journal.pone.0055071.
94. Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol (2003) 24(5):242-8. doi:10.1016/S1471-4906(03)00072-3.
95. Katz JD, Janssen EM. Breaking T cell tolerance to beta cell antigens by merocytic dendritic cells. Cell Mol Life Sci (2011) 68(17):2873-83. doi:10.1007/s00018-011-0730-6.
96. Katz JD, Ondr JK, Opoka RJ, Garcia Z, Janssen EM. Cutting edge: merocytic dendritic cells break T cell tolerance to beta cell antigens in nonobese diabetic mouse diabetes. J Immunol (2010) 185(4):1999-2003. doi:10.4049/jimmunol.1001398.
97. Pelletier AN, Lesage S. The Idd13 congenic interval defines the number of merocytic dendritic cells, a novel trait associated with autoimmune diabetes susceptibility. J Autoimmun (2013) 43:70-7. doi:10.1016/j.jaut.2013.04.004.
98. Calderon B, Suri A, Miller MJ, Unanue ER. Dendritic cells in islets of Langerhans constitutively present beta cell-derived peptides bound to their class II MHC molecules. Proc Natl Acad Sci U S A (2008) 105(16):6121-6. doi:10.1073/pnas.0801973105.
99. Melli K, Friedman RS, Martin AE, Finger EB, Miao G, Szot GL, et al. Amplification of autoimmune response through induction of dendritic cell maturation in inflamed tissues. J Immunol (2009) 182(5):2590-600. doi:10.4049/jimmunol.0803543.
100. Ginhoux F, Liu K, Helft J, Bogunovic M, Greter M, Hashimoto D, et al. The origin and development of nonlymphoid tissue CD103+ DCs. J Exp Med (2009) 206(13):3115-30. doi:10.1084/jem.20091756.
101. Yin N, Xu J, Ginhoux F, Randolph GJ, Merad M, Ding Y, et al. Functional specialization of islet dendritic cell subsets. J Immunol (2012) 188(10):4921-30. doi:10.4049/jimmunol.1103725.
102. Calderon B, Carrero JA, Miller MJ, Unanue ER. Cellular and molecular events in the localization of diabetogenic T cells to islets of Langerhans. Proc Natl Acad Sci U S A (2011) 108(4):1561-6. doi:10.1073/pnas.1018973108.
103. Gagnerault MC, Luan JJ, Lotton C, Lepault F. Pancreatic lymph nodes are required for priming of beta cell reactive T cells in NOD mice. J Exp Med (2002) 196(3):369-77. doi:10.1084/jem.20011353.
104. Hoglund P, Mintern J, Waltzinger C, Heath W, Benoist C, Mathis D. Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J Exp Med (1999) 189(2):331-9. doi:10.1084/jem.189.2.331.
105. Zhang Y, O'Brien B, Trudeau J, Tan R, Santamaria P, Dutz JP. In situ beta cell death promotes priming of diabetogenic CD8 T lymphocytes. J Immunol (2002) 168(3):1466-72.
106. Coppieters K, Martinic MM, Kiosses WB, Amirian N, von Herrath M. A novel technique for the in vivo imaging of autoimmune diabetes development in the pancreas by two-photon microscopy. PLoS One (2010) 5(12):e15732. doi:10.1371/journal.pone.0015732.
107. Welzen-Coppens JM, van Helden-Meeuwsen CG, Leenen PJ, Drexhage HA, Versnel MA. Reduced numbers of dendritic cells with a tolerogenic phenotype in the prediabetic pancreas of NOD mice. J Leukoc Biol (2012) 92(6):1207-13. doi:10.1189/jlb.0312168.
108. Allen JS, Pang K, Skowera A, Ellis R, Rackham C, Lozanoska-Ochser B, et al. Plasmacytoid dendritic cells are proportionally expanded at diagnosis of type 1 diabetes and enhance islet autoantigen presentation to T-cells through immune complex capture. Diabetes (2009) 58(1):138-45. doi:10.2337/db08-0964.
109. Vuckovic S, Withers G, Harris M, Khalil D, Gardiner D, Flesch I, et al. Decreased blood dendritic cell counts in type 1 diabetic children. Clin Immunol (2007) 123(3):281-8. doi:10.1016/j.clim.2007.03.002.
110. Galgani M, Nugnes R, Bruzzese D, Perna F, De Rosa V, Procaccini C, et al. Meta-immunological profiling of children with type 1 diabetes identifies new biomarkers to monitor disease progression. Diabetes (2013) 62(7):2481-91. doi:10.2337/db12-1273.
111. Nieminen JK, Vakkila J, Salo HM, Ekstrom N, Harkonen T, Ilonen J, et al. Altered phenotype of peripheral blood dendritic cells in pediatric type 1 diabetes. Diabetes Care (2012) 35(11):2303-10. doi:10.2337/dc11-2460.
112. Rose K, Penna-Martinez M, Klahold E, Karger D, Shoghi F, Kahles H, et al. Influence of the vitamin D plasma level and vitamin D-related genetic polymorphisms on the immune status of patients with type 1 diabetes: a pilot study. Clin Exp Immunol (2013) 171(2):171-85. doi:10.1111/cei.12013.
113. Uno S, Imagawa A, Okita K, Sayama K, Moriwaki M, Iwahashi H, et al. Macrophages and dendritic cells infiltrating islets with or without beta cells produce tumour necrosis factor-alpha in patients with recent-onset type 1 diabetes. Diabetologia (2007) 50(3):596-601. doi:10.1007/s00125-006-0569-9.
114. Aida K, Nishida Y, Tanaka S, Maruyama T, Shimada A, Awata T, et al. RIG-I-and MDA5-initiated innate immunity linked with adaptive immunity accelerates beta-cell death in fulminant type 1 diabetes. Diabetes (2011) 60(3):884-9. doi:10.2337/db10-0795.
115. Mukherjee G, Dilorenzo TP. The immunotherapeutic potential of dendritic cells in type 1 diabetes. Clin Exp Immunol (2010) 161(2):197-207. doi:10.1111/j.1365-2249.2010.04157.x.
116. Morel PA, Feili-Hariri M, Coates PT, Thomson AW. Dendritic cells, T cell tolerance and therapy of adverse immune reactions. Clin Exp Immunol (2003) 133(1):1-10. doi:10.1046/j.1365-2249.2003.02161.x.
117. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol (2007) 7(8):610-21. doi:10.1038/nri2132.
118. Menges M, Rossner S, Voigtlander C, Schindler H, Kukutsch NA, Bogdan C, et al. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exp Med (2002) 195(1):15-21. doi:10.1084/jem.20011341.
119. Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol (2002) 23(9):445-9. doi:10.1016/S1471-4906(02)02281-0.
120. Clemente-Casares X, Tsai S, Huang C, Santamaria P. Antigen-specific therapeutic approaches in Type 1 diabetes. Cold Spring Harbor Perspect Med (2012) 2(2):a007773. doi:10.1101/cshperspect.a007773.
121. Clare-Salzler MJ, Brooks J, Chai A, Van Herle K, Anderson C. Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer. J Clin Invest (1992) 90(3):741-8. doi:10.1172/JCI115946.
122. Naumov YN, Bahjat KS, Gausling R, Abraham R, Exley MA, Koezuka Y, et al. Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc Natl Acad Sci U S A (2001) 98(24):13838-43. doi:10.1073/pnas.251531798.
123. Feili-Hariri M, Dong X, Alber SM, Watkins SC, Salter RD, Morel PA. Immunotherapy of NOD mice with bone marrow-derived dendritic cells. Diabetes (1999) 48:2300-8. doi:10.2337/diabetes.48.12.2300.
124. Feili-Hariri M, Falkner DH, Gambotto A, Papworth GD, Watkins SC, Robbins PD, et al. Dendritic cells transduced to express IL-4 prevent diabetes in nonobese diabetic mice with established insulitis. Human Gene Ther (2003) 14:13-23. doi:10.1089/10430340360464679.
125. Feili-Hariri M, Falkner DH, Morel PA. Regulatory Th2 response induced following adoptive transfer of dendritic cells in prediabetic NOD mice. Eur J Immunol (2002) 32:2021-30. doi:10.1002/1521-4141(200207)32:7<2021::AID-IMMU2021>3.0.CO;2-J.
126. Creusot RJ, Chang P, Healey DG, Tcherepanova IY, Nicolette CA, Fathman CG. A short pulse of IL-4 delivered by DCs electroporated with modified mRNA can both prevent and treat autoimmune diabetes in NOD mice. Mol Ther (2010) 18(12):2112-20. doi:10.1038/mt.2010.146.
127. Ruffner MA, Robbins PD. Dendritic cells transduced to express interleukin 4 reduce diabetes onset in both normoglycemic and prediabetic nonobese diabetic mice. PLoS One (2010) 5(7):e11848. doi:10.1371/journal.pone.0011848.
128. Haase C, Ejrnaes M, Juedes AE, Wolfe T, Markholst H, von Herrath MG. Immunomodulatory dendritic cells require autologous serum to circumvent nonspecific immunosuppressive activity in vivo. Blood (2005) 106(13):4225-33. doi:10.1182/blood-2005-03-0975.
129. Turner MS, Kane LP, Morel PA. Dominant role of antigen dose in CD4+Foxp3+ regulatory T cell induction and expansion. J Immunol (2009) 183(8):4895-903. doi:10.4049/jimmunol.0901459.
130. Haase C, Yu L, Eisenbarth G, Markholst H. Antigen-dependent immunotherapy of non-obese diabetic mice with immature dendritic cells. Clin Exp Immunol (2010) 160(3):331-9. doi:10.1111/j.1365-2249.2010.04104.x.
131. Tai N, Yasuda H, Xiang Y, Zhang L, Rodriguez-Pinto D, Yokono K, et al. IL-10-conditioned dendritic cells prevent autoimmune diabetes in NOD and humanized HLA-DQ8/RIP-B7.1 mice. Clin Immunol (2011) 139(3):336-49. doi:10.1016/j.clim.2011.03.003.
132. Torres-Aguilar H, Sanchez-Torres C, Jara LJ, Blank M, Shoenfeld Y. IL-10/TGF-beta-treated dendritic cells, pulsed with insulin, specifically reduce the response to insulin of CD4+ effector/memory T cells from type 1 diabetic individuals. J Clin Immunol (2010) 30(5):659-68. doi:10.1007/s10875-010-9430-5.
133. Besin G, Gaudreau S, Menard M, Guindi C, Dupuis G, Amrani A. Thymic stromal lymphopoietin and thymic stromal lymphopoietin-conditioned dendritic cells induce regulatory T-cell differentiation and protection of NOD mice against diabetes. Diabetes (2008) 57(8):2107-17. doi:10.2337/db08-0171.
134. Kleijwegt FS, Jansen DT, Teeler J, Joosten AM, Laban S, Nikolic T, et al. Tolerogenic dendritic cells impede priming of naive CD8(+) T cells and deplete memory CD8(+) T cells. Eur J Immunol (2013) 43(1):85-92. doi:10.1002/eji.201242879.
135. Simon T, Pogu S, Tardif V, Rigaud K, Remy S, Piaggio E, et al. Carbon monoxide-treated dendritic cells decrease beta1-integrin induction on CD8(+) T cells and protect from type 1 diabetes. Eur J Immunol (2013) 43(1):209-18. doi:10.1002/eji.201242684.
136. Karumuthil-Melethil S, Perez N, Li R, Prabhakar BS, Holterman MJ, Vasu C. Dendritic cell-directed CTLA-4 engagement during pancreatic beta cell antigen presentation delays type 1 diabetes. J Immunol (2010) 184(12):6695-708. doi:10.4049/jimmunol.0903130.
137. Diana J, Moura IC, Vaugier C, Gestin A, Tissandie E, Beaudoin L, et al. Secretory IgA induces tolerogenic dendritic cells through SIGNR1 dampening autoimmunity in mice. J Immunol (2013) 191(5):2335-43. doi:10.4049/jimmunol.1300864.
138. Machen J, Harnaha J, Lakomy R, Styche A, Trucco M, Giannoukakis N. Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells. J Immunol (2004) 173(7):4331-41.
139. Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care (2011) 34(9):2026-32. doi:10.2337/dc11-0472.
140. Tarbell KV, Yamazaki S, Steinman RM. The interactions of dendritic cells with antigen-specific, regulatory T cells that suppress autoimmunity. Semin Immunol (2006) 18(2):93-102. doi:10.1016/j.smim.2006.01.009.
141. Gopisetty A, Bhattacharya P, Haddad C, Bruno JC Jr, Vasu C, Miele L, et al. OX40L/Jagged1 cosignaling by GM-CSF-induced bone marrow-derived dendritic cells is required for the expansion of functional regulatory T cells. J Immunol (2013) 190(11):5516-25. doi:10.4049/jimmunol.1202298.
142. Moreau A, Varey E, Bouchet-Delbos L, Cuturi MC. Cell therapy using tolerogenic dendritic cells in transplantation. Transplant Res (2012) 1(1):13. doi:10.1186/2047-1440-1-13.
143. Boks MA, Kager-Groenland JR, Haasjes MSP, Zwaginga JJ, van Ham SM, ten Brinke A. IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction-a comparative study of human clinical-applicable DC. Clin Immunol (2012) 142(3):332-42. doi:10.1016/j.clim.2011.11.011.
144. Petzold C, Riewaldt J, Koenig T, Schallenberg S, Kretschmer K. Dendritic cell-targeted pancreatic beta-cell antigen leads to conversion of self-reactive CD4(+) T cells into regulatory T cells and promotes immunotolerance in NOD mice. Rev Diabet Stud (2010) 7(1):47-61. doi:10.1900/RDS.2010.7.47.
145. Bruder D, Westendorf AM, Hansen W, Prettin S, Gruber AD, Qian Y, et al. On the edge of autoimmunity: T-cell stimulation by steady-state dendritic cells prevents autoimmune diabetes. Diabetes (2005) 54(12):3395-401. doi:10.2337/diabetes.54.12.3395.
146. Mukhopadhaya A, Hanafusa T, Jarchum I, Chen YG, Iwai Y, Serreze DV, et al. Selective delivery of beta cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8+ T cells in NOD mice. Proc Natl Acad Sci U S A (2008) 105(17):6374-9. doi:10.1073/pnas.0802644105.
147. Constant S, Pfeiffer C, Woodard A, Pasqualini T, Bottomly K. Extent of T cell receptor ligation can determine the functional differentiation of naive CD4+ T cells. J Exp Med (1995) 182(5):1591-6. doi:10.1084/jem.182.5.1591.
148. Constant SL, Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol (1997) 15:297-322. doi:10.1146/annurev.immunol.15.1.297.
149. Hosken NA, Shibuya K, Heath AW, Murphy KM, O'Garra A. The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model. J Exp Med (1995) 182(5):1579-84. doi:10.1084/jem.182.5.1579.
150. Sauer S, Bruno L, Hertweck A, Finlay D, Leleu M, Spivakov M, et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A (2008) 105(22):7797-802. doi:10.1073/pnas.0800928105.
151. Gabryšová L, Christensen JR, Wu X, Kissenpfennig A, Malissen B, O'Garra A. Integrated T-cell receptor and costimulatory signals determine TGF-ββ-dependent differentiation and maintenance of Foxp3+ regulatory T cells. Eur J Immunol (2011) 41(5):1242-8. doi:10.1002/eji.201041073.
152. Gottschalk RA, Corse E, Allison JP. TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo. J Exp Med (2010) 207(8):1701-11. doi:10.1084/jem.20091999.
153. Gottschalk RA, Hathorn MM, Beuneu H, Corse E, Dustin ML, Altan-Bonnet G, et al. Distinct influences of peptide-MHC quality and quantity on in vivo T-cell responses. Proc Natl Acad Sci U S A (2012) 109(3):881-6. doi:10.1073/pnas.1119763109.
154. von Boehmer H. Peptide-based instruction of suppressor commitment in naive T cells and dynamics of immunosuppression in vivo. Scand J Immunol (2005) 62(Suppl 1):49-54. doi:10.1111/j.1365-3083.2005.01609.x.
155. Daniel C, Weigmann B, Bronson R, von Boehmer H. Prevention of type 1 diabetes in mice by tolerogenic vaccination with a strong agonist insulin mimetope. J Exp Med (2011) 208(7):1501-10. doi:10.1084/jem.20110574.
156. Long SA, Rieck M, Tatum M, Bollyky PL, Wu RP, Muller I, et al. Low-dose antigen promotes induction of FOXP3 in human CD4+ T cells. J Immunol (2011) 187(7):3511-20. doi:10.4049/jimmunol.1003880.
157. Keselowsky BG, Xia CQ, Clare-Salzler M. Multifunctional dendritic cell-targeting polymeric microparticles: engineering new vaccines for type 1 diabetes. Hum Vaccin (2011) 7(1):37-44. doi:10.4161/hv.7.1.12916.
158. Phillips B, Nylander K, Harnaha J, Machen J, Lakomy R, Styche A, et al. A microsphere-based vaccine prevents and reverses new-onset autoimmune diabetes. Diabetes (2008) 57(6):1544-55. doi:10.2337/db07-0507.
159. Hu C, Ding H, Zhang X, Wong FS, Wen L. Combination treatment with anti-CD20 and oral anti-CD3 prevents and reverses autoimmune diabetes. Diabetes (2013) 62(8):2849-58. doi:10.2337/db12-1175.
160. Fallarino F, Bianchi R, Orabona C, Vacca C, Belladonna ML, Fioretti MC, et al. CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J Exp Med (2004) 200(8):1051-62. doi:10.1084/jem.20040942.
161. Billiard F, Lobry C, Darrasse-Jeze G, Waite J, Liu X, Mouquet H, et al. Dll4-Notch signaling in Flt3-independent dendritic cell development and autoimmunity in mice. J Exp Med (2012) 209(5):1011-28. doi:10.1084/jem.20111615.
162. Hong S, Wilson MT, Serizawa I, Wu L, Singh N, Naidenko OV, et al. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med (2001) 7(9):1052-6. doi:10.1038/nm0901-1052.
163. Sharif S, Arreaza GA, Zucker P, Mi QS, Sondhi J, Naidenko OV, et al. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med (2001) 7(9):1057-62. doi:10.1038/nm0901-1057.
164. Wang B, Geng YB, Wang CR. CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J Exp Med (2001) 194(3):313-20. doi:10.1084/jem.194.3.313.
165. Wang J, Cho S, Ueno A, Cheng L, Xu BY, Desrosiers MD, et al. Ligand-dependent induction of noninflammatory dendritic cells by anergic invariant NKT cells minimizes autoimmune inflammation. J Immunol (2008) 181(4):2438-45.
166. Tohn R, Blumenfeld H, Haeryfar SM, Veerapen N, Besra GS, Porcelli SA, et al. Stimulation of a shorter duration in the state of anergy by an invariant natural killer T cell agonist enhances its efficiency of protection from type 1 diabetes. Clin Exp Immunol (2011) 164(1):26-41. doi:10.1111/j.1365-2249.2011.04323.x.
167. Di Caro V, Phillips B, Engman C, Harnaha J, Trucco M, Giannoukakis N. Retinoic acid-producing, ex vivo-generated human tolerogenic dendritic cells induce the proliferation of immunosuppressive B-lymphocytes. Clin Exp Immunol (2013) 174(2):302-17. doi:10.1111/cei.12177.
168. Coppieters KT, Harrison LC, von Herrath MG. Trials in type 1 diabetes: antigen-specific therapies. Clin Immunol (2013) 149(3):345-55. doi:10.1016/j.clim.2013.02.002.
169. Shoda LK, Young DL, Ramanujan S, Whiting CC, Atkinson MA, Bluestone JA, et al. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity (2005) 23(2):115-26. doi:10.1016/j.immuni.2005.08.002.